252 results
Page 2 of 13
DEFM14A
7j7a5gd0c7kbvzjvlo2
13 Apr 23
Proxy related to merger
4:52pm
424B5
11ffi9z cll7
23 Sep 22
Prospectus supplement for primary offering
5:05pm
8-K
EX-99.1
p3dyqz9hhznue d5uc
21 Sep 22
Adamis Provides Update on the Phase 2/3 Trial of Tempol in COVID-19 Positive High-Risk Subjects
4:10pm
8-K
eperfo6r 7bl
21 Sep 22
Adamis Provides Update on the Phase 2/3 Trial of Tempol in COVID-19 Positive High-Risk Subjects
4:10pm
DEFA14A
jet6aewf8lx
18 Aug 22
Additional proxy soliciting materials
3:07pm
8-K
EX-99.1
ujesoh9h7b4q
10 Aug 22
Adamis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
4:09pm
8-K
EX-99.1
3rfoy8ico
1 Aug 22
Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19
6:10am
8-K
a629i2pqdfo
1 Aug 22
Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19
6:10am
DEFA14A
EX-10.1
hp1qz3m7w5g8 329
6 Jul 22
Additional proxy soliciting materials
6:04am
8-K
EX-10.1
yo8nrt
6 Jul 22
Entry into a Material Definitive Agreement
6:04am
8-K
EX-10.1
odbp1e5 feap40
24 Jun 22
Entry into a Material Definitive Agreement
4:35pm
8-K
EX-3.1
7unb q0ly3fr
17 Jun 22
Material Modifications to Rights of Security Holders
4:25pm
8-K
EX-10.1
q6f6bb5ywddm4v1o
18 May 22
Adamis Pharmaceuticals Announces Leadership Transition to Support New Phase of Innovation and Growth
7:53pm
8-K
EX-10.2
uuqtc5xwesuumerasnp
18 May 22
Adamis Pharmaceuticals Announces Leadership Transition to Support New Phase of Innovation and Growth
7:53pm
8-K
EX-99.1
0qat7j2z sk8i8ukc
18 May 22
Adamis Pharmaceuticals Announces Leadership Transition to Support New Phase of Innovation and Growth
7:53pm